Suining Central Hospital
8
3
3
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
IAT-MeVO Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial
Role: collaborator
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
Role: collaborator
Drain Removal on Postoperative Safety and Patient Satisfaction in R-E-NSM With Prepectoral DIBR
Role: collaborator
Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
Role: collaborator
A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP
Role: collaborator
Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy
Role: collaborator
Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China
Role: collaborator
Prediction of Adverse Perinatal Outcome for Preeclampsia in Sichuan Province of China
Role: collaborator
All 8 trials loaded